Dashboard
1
With a growth in Net Sales of 51.63%, the company declared Very Positive results in Mar 25
- The company has declared positive results in Jan 70 after 6 consecutive negative quarters
- NET PROFIT(HY) Higher at CNY 19.57 MM
2
With ROE of 0.89%, it has a fair valuation with a 0.86 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,984 Million (Small Cap)
97.00
NA
0.20%
0.11
3.12%
0.81
Revenue and Profits:
Net Sales:
593 Million
(Quarterly Results - Sep 2025)
Net Profit:
113 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.55%
0%
10.55%
6 Months
-19.92%
0%
-19.92%
1 Year
2.4%
0%
2.4%
2 Years
-9.1%
0%
-9.1%
3 Years
0.63%
0%
0.63%
4 Years
0.16%
0%
0.16%
5 Years
-3.03%
0%
-3.03%
Guangdong Shirongzhaoye Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-14.84%
EBIT Growth (5y)
-57.06%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.92
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0.24
Tax Ratio
58.54%
Dividend Payout Ratio
21.65%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.77%
ROE (avg)
8.87%
Valuation key factors
Factor
Value
P/E Ratio
97
Industry P/E
Price to Book Value
0.86
EV to EBIT
297.97
EV to EBITDA
89.26
EV to Capital Employed
0.88
EV to Sales
4.83
PEG Ratio
NA
Dividend Yield
0.20%
ROCE (Latest)
0.29%
ROE (Latest)
0.89%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
592.90
176.60
235.73%
Operating Profit (PBDIT) excl Other Income
117.60
10.90
978.90%
Interest
4.00
0.80
400.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
113.00
2.70
4,085.19%
Operating Profit Margin (Excl OI)
198.40%
27.00%
17.14%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 235.73% vs -72.28% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 4,085.19% vs -98.09% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
976.50
1,542.60
-36.70%
Operating Profit (PBDIT) excl Other Income
96.50
321.70
-70.00%
Interest
3.10
0.60
416.67%
Exceptional Items
-9.20
0.00
Consolidate Net Profit
57.30
224.30
-74.45%
Operating Profit Margin (Excl OI)
73.80%
193.40%
-11.96%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -36.70% vs 86.91% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -74.45% vs 54.58% in Dec 2023
About Guangdong Shirongzhaoye Co., Ltd. 
Guangdong Shirongzhaoye Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






